Michael H. Brave

Michael H. Brave

Auto-generated profile, based on publicly available information

Michael H. Brave

Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2008 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MBMichael Brave
Michael Brave
VGVicki Goodman
Vicki Goodman
EKEdvardas Kaminskas
Edvardas Kaminskas
AFAnn Farrell
Ann Farrell
WTWilliam Timmer
William Timmer
RPRichard Pazdur
Richard Pazdur
Purpose: On June 28, 2006, the U.S. Food and Drug Administration approved dasatinib (Sprycel; Bristol-Myers Squibb), a new small-molecule inhibitor of multiple tyrosine kinases, for the treatment of adults with chronic phase, accelerated phase, or myeloid or lymphoid blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy including imatinib. This summary reviews the database supporting this approval. Experimental Design: Four single-arm multicenter studies supported the efficacy and safety of dasatinib. The primary efficacy end point in chronic phase CML was major cytogenetic response. The primary end point in accelerated phase, myeloid phase, and lymphoid blast phase CML, and Ph+ ALL was major hematologic response. Results: The four studies combined enrolled 445 patients. In patients with chronic phase CML, the major cytogenetic response rate was 45% with a complete cytogenetic response rate of 33%. Major hematologic response rates in patients with accelerated phase CML, myeloid CML, lymphoid blast CML, and Ph+ ALL were 59%, 32%, 31%, and 42%, respectively. Median response durations in chronic phase, accelerated phase, and myeloid phase CML had not been reached. The median durations of major hematologic response were 3.7 months in lymphoid blast CML and 4.8 months in Ph+ ALL. Common toxicities with dasatinib included myelosuppression, bleeding, and fluid retention. Conclusions: This report describes the Food and Drug Administration review supporting the approval of dasatinib for CML and Ph+ ALL based on the rates and durability of cytogenetic and hematologic responses.

1 June 2010 in Oncology
Verified
Journal Article
Closed access
MBMichael Brave
Michael Brave
AFAnn Farrell
Ann Farrell
SLSue Ching Lin
Sue Ching Lin
TOTerrance Ocheltree
Terrance Ocheltree
SMSarah Pope Miksinski
Sarah Pope Miksinski
RPRichard Pazdur
Richard Pazdur
Purpose: On December 15, 2008, the US Food and Drug Administration approved plerixafor (Mozobil®; Genzyme Corp.), a new small-molecule inhibitor of the CXCR4 chemokine receptor, for use in combination with granulocyte colony-stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSC) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM). This summary reviews the database supporting this approval. Experimental Design: The safety and efficacy of plerixafor were demonstrated by 2 multicenter, randomized, placebo-controlled studies in patients with NHL and MM who were eligible for autologous HSC transplantation. The primary efficacy end points were the collection of ≧5 × 106 CD34+ cells/kg from the peripheral blood in 4 or fewer apheresis sessions in patients with NHL or ≧6 × 106 CD34+ cells/kg from the peripheral blood in 2 or fewer apheresis sessions in patients with MM. Results: The 2 randomized studies combined enrolled 600 patients (298 with NHL and 302 with MM). Fifty-nine percent of patients with NHL who were mobilized with G-CSF and plerixafor had peripheral blood HSC collections of ≧5 × 106 CD34+ cells/kg in 4 or fewer apheresis sessions, compared with 20% of patients with NHL who were mobilized with G-CSF and placebo (p < 0.001). Seventy-two percent of patients with MM who were mobilized with Mozobil and G-CSF had peripheral blood HSC collections of ≧6 × 106 CD34+ cells/kg in 2 or fewer apheresis sessions, compared with 34% of patients with MM who were mobilized with placebo and G-CSF (p < 0.001). Common adverse reactions included diarrhea, nausea, vomiting, flatulence, injection site reactions, fatigue, arthralgia, headache, dizziness, and insomnia. Conclusions: This report describes the Food and Drug Administration review supporting the approval of plerixafor.

4 September 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
MBMichael H. Brave
Michael H. Brave
WMWilliam F. Maguire
William F. Maguire
CWChana Weinstock
Chana Weinstock
HZHui Zhang
Hui Zhang
XGXin Gao
Xin Gao
DSDaniel L. Suzman
Daniel L. Suzman
On December 15, 2023, the FDA granted traditional approval to enfortumab vedotin-ejfv plus pembrolizumab (EV + Pembro) for patients with locally advanced or metastatic urothelial carcinoma (la/mUC). Substantial evidence of effectiveness was obtained from EV-302/KEYNOTE-A39 (NCT04223856), an open-label, randomized trial evaluating EV + Pembro versus cisplatin or carboplatin plus gemcitabine (Plat + Gem) in patients with previously untreated la/mUC. A total of 886 patients were randomized (1:1) to receive EV 1.25 mg/kg intravenously on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity plus Pembro 200 mg intravenously on day 1 of each 21-day cycle for up to 35 cycles or Plat + Gem for up to 6 cycles. Dual primary endpoints were progression-free survival determined by blinded independent central review and overall survival. The median progression-free survival was 12.5 months [95% confidence interval (CI), 10.4–16.6] in the EV + Pembro arm and 6.3 months (95% CI, 6.2–6.5) in the Plat + Gem arm [HR, 0.450 (95% CI, 0.377–0.538); P value < 0.0001]. The median overall survival was 31.5 months (95% CI, 25.4–not estimable) in the EV + Pembro arm and 16.1 months (95% CI, 13.9–18.3) in the Plat + Gem arm [HR, 0.468 (95% CI, 0.376–0.582); P value < 0.0001]. The safety profile of EV + Pembro was similar to that observed in EV-103/KEYNOTE-869 in cisplatin-ineligible patients with la/mUC. This article summarizes the data and the FDA thought process supporting traditional approval of EV + Pembro, as well as additional exploratory analyses conducted by the FDA.

15 September 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MBMichael Brave
Michael Brave
CWChana Weinstock
Chana Weinstock
JBJamie R. Brewer
Jamie R. Brewer
DCDow-Chung Chi
Dow-Chung Chi
DSDaniel L. Suzman
Daniel L. Suzman
JBJulia A. Beaver
Julia A. Beaver
The FDA has approved three androgen receptor inhibitors—enzalutamide, apalutamide, and darolutamide—for the treatment of patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). These approvals were all based on randomized, double blind, placebo-controlled trials demonstrating large improvements in metastasis-free survival (MFS) and internally consistent evidence of benefit seen across secondary endpoints. In this article, we summarize the FDA regulatory history of MFS and we describe the design, conduct, and results of the three pivotal trials supporting these important treatment options for patients with nmCRPC.


1 October 2006
Verified
Journal Article
Closed access
MBMichael Brave
Michael Brave
RDRamzi Dagher
Ramzi Dagher
AFAnn Farrell
Ann Farrell
SASophia Abraham
Sophia Abraham
RRRoshni Ramchandani
Roshni Ramchandani
RPRichard Pazdur
Richard Pazdur